Concepedia

Ruth Bylund

RB

4

Publications

419

Citations

4

H-Index

1995

Active since

Affiliations

AstraZeneca (Sweden)(Current)

Ruth Bylund is an author at AstraZeneca (Sweden) specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

MedicinePharmacologyPharmacotherapyThrombosisBiochemistryDrug DiscoveryHematologyMolecular PharmacologyImmunologyDrug Analysis

Publications per year

1995–2013

4

Publications

4

The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects

David Gustafsson, Jan-Erik Nyström, Stefan Carlsson et al. · Thrombosis Research · 2001 · 302 citations

Pharmaceutical Science, Biochemistry, Medicine +5

Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y<sub>12</sub> Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283

Peter Bach, Thomas Antonsson, Ruth Bylund et al. · Journal of Medicinal Chemistry · 2013 · 63 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +20

IN VITRO EFFECTS OF INOGATRAN, A SELECTIVE LOW MOLECULAR WEIGHT THROMBIN INHIBITOR

Ann‐Catrine Teger‐Nilsson, Ruth Bylund, David Gustafsson et al. · Thrombosis Research · 1997 · 43 citations

Thrombopoiesis, Molecular Pharmacology, Thrombosis +10

931-115 Phase I Studies on Inogatran, a New Selective Thrombin Inhibitor

Ann‐Catrine Teger‐Nilsson, Ulf G. Eriksson, David Gustafsson et al. · Journal of the American College of Cardiology · 1995 · 11 citations

Thrombopoiesis, Thrombosis, 931-115 Phase +9

Rows per page

1–4 of 4